MammaTrace – a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer David N. Buckley

457 days. That’s the median lead time between a positive MammaTrace result and clinically confirmed breast cancer recurrence.

Long-time myBaits customer Bodour Salhia and colleagues developed MammaTrace, a plasma-only cfDNA methylation assay designed to detect minimal residual disease (MRD).

The study demonstrated 91% sensitivity and 83% specificity for MRD detection in early-stage breast cancer.

Explore the research and see how targeted enrichment is helping advance liquid biopsy and MRD surveillance.